$400,000 – Awarded 2026
Awarded 2024
Sacyl Pharmaceuticals
Cary, NC
About
Sacyl Pharmaceuticals is a pioneering biotech company developing novel, non-hormonal, and reversible male contraceptive options. Their research focuses on Soluble Adenylyl Cyclase (sAC), an enzyme vital for sperm motility. By inhibiting sAC, Sacyl aims to temporarily immobilize sperm without affecting hormones or long-term fertility. This work is geared toward creating on-demand, user-controlled male contraception, addressing a major gap in family planning and promoting reproductive equity. The development of a reversible male pill is considered a highly disruptive innovation in the reproductive health landscape. Sacyl’s approach offers a potential alternative to permanent sterilization or existing methods that often have side effects.
Our Grant
MCI’s crucial support is instrumental in advancing the development of a novel, non-hormonal male contraceptive. Specifically, the funding and resources provided by MCI are facilitating the essential steps for the Investigational New Drug (IND) Enablement of a clinical-lead Soluble Adenylyl Cyclase (sAC) inhibitor. This cutting-edge compound is being developed as an on-demand contraceptive, offering men a reversible and convenient option for fertility control. The goal of this support is to accelerate the preclinical and manufacturing work necessary to file an IND application with regulatory bodies, thereby moving this promising male contraceptive candidate closer to clinical trials and, ultimately, to market.